Seclidemstat 是一种有效的非竞争性可逆 KDM1A (LSD1) 抑制剂 (K_i=31 nM, IC₅₀)。Seclidemstat 促进 SWI/SNF 复合物突变卵巢癌的抗肿瘤免疫，并抑制病毒产生、病毒 DNA 复制和晚期基因表达。Seclidemstat 可用于尤文肉瘤的研究。

Seclidemstat is a potent noncompetitive and reversible KDM1A (LSD1) inhibitor (K i =31 nM, IC 50 =13 nM). Seclidemstat promotes antitumor immunity in switch/sucrose nonfermentable (SWI/SNF) complex mutated ovarian cancer, as well as inhibit virus production, viral DNA replication, and late gene expression. Seclidemstat can be used for the research of Ewing Sarcoma.

Solid

Ki: 31 nM (LSD1)
IC50: 13 nM (LSD1)

Seclidemstat (72 hours) inhibits SWI/SNF-mutation-dependent tumor cell proliferation with IC50 ranging from 0.013 to 2.819 μM (COV434, BIN67, SCCOHT-1, TOV21G, SKOV3, A427, H522, A549, H1299, G401, G402, HCC15 cells).
Seclidemstat (72 hours) promotes endogenous retroviruses (ERVs) expression and activation of IFNβ pathway in SCCOHT cell lines (SCCOHT-1, BIN67, and COV434 cells).
Seclidemstat (3 μM) promotes PD-L1 expression in SCCOHT COV 434 pIND 20 BRG1-2.7 cell line. has not independently confirmed the accuracy of these methods. They are for reference only.

Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years；4°C 2 years

[1]. Dai XJ, et al. Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1 [published correction appears in J Med Chem. 2021 May 13;64(9):6410-6411]. J Med Chem. 2021;64(5):2466-2488.
[2]. Soldi R, et al. The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer. PLoS One. 2020;15(7):e0235705. Published 2020 Jul 10.

In Vitro: DMSO : 50 mg/mL (110.88 mM; ultrasonic and warming and heat to 80°C)配制储备液